BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 2,075,291 shares of Crescent BioPharma Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 2,075,291 shares of Crescent BioPharma Inc. common stock.
  • Percent of class: The reported position represents 5.6% of the outstanding common shares, according to the filing.
  • Sole voting power: BlackRock disclosed sole voting power over 2,034,925 shares.
  • Sole dispositive power: BlackRock disclosed sole dispositive power over 2,075,291 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power were reported as 0.
  • Event date: The date of the event requiring this filing was September 30, 2026.
  • Filer type: BlackRock identified itself as a parent holding company or control person (type HC), incorporated in Delaware.

BlackRock's Reported Ownership Position in Crescent BioPharma

According to the Schedule 13G filed on October 27, 2026, BlackRock, Inc., headquartered at 50 Hudson Yards, New York, NY 10001, reported that certain of its business units beneficially own 2,075,291 shares of common stock in Crescent BioPharma Inc. (CUSIP G2545C104). The filing states that the position represents 5.6% of the issuer's outstanding common shares. Crescent BioPharma Inc. is listed with its principal offices at 300 Fifth Avenue, Waltham, MA 02451.

The filing discloses that BlackRock holds sole voting power over 2,034,925 shares and sole dispositive power over 2,075,291 shares, with no shared voting or dispositive power reported. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 27, 2026.

As stated in the filing, this Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and does not include securities held by other business units whose beneficial ownership has been disaggregated. The filing further states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Crescent BioPharma Inc.," and that no single person's interest exceeds five percent of the total outstanding common shares. The identity of relevant subsidiaries is provided in Exhibit 99 attached to the filing.

What Was Disclosed

BlackRock, Inc. filed a Schedule 13G reporting beneficial ownership of 2,075,291 shares, or 5.6%, of Crescent BioPharma Inc. common stock as of September 30, 2026, with all voting and dispositive power held on a sole basis.